Brüggenjürgen, B, Andersohn, F, Burkowitz, J, Ezzat, N, Gaudig, M, Willich, SN (2016). Cohort Study on Predictors of Need for Nursing Care in Alzheimer’s Disease: An Analysis of Healthcare Data. Journal of Alzheimer’s Disease. doi: 10.3233/JAD-160137
Burkowitz J, Merzenich, C, Grassme K, Brüggenjürgen B (2016). Insertable Cardiac Monitors in the Diagnosis of Syncope and the Detection of Atrial Fibrillation: A Systematic Review and Meta-Analysis. European Journal of Preventative Cardiology. doi: 10.1177/2047487316632628
Aggarwal J, Vera-Llonch M, Donepudi M, Suthoff E, Younossi Z and Goss TF. (2014), Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. Journal of Viral Hepatitis. doi: 10.1111/jvh.12227
Association of Community Cancer Centers (ACCC), the Biotechnology Industry Organization (BIO), Boston Healthcare Associates, Inc., and Pharmaceutical Research and Manufacturers of America (PhRMA) (March/April 2014). Physician Survey of Impact of Payer Policies on Medically Appropriate Off-Label Use. Oncology Issues: Journal of the Association of Community Cancer Centers (ACCC).
Bücheler M, Brüggenjürgen B, Willich S (2014). Personalized Medicine In Europe – Enhancing Patient Access To Pharmaceutical Drug-Diagnostic Companion Products. EPEMED: Patient Access Study 2012 – 2013.
Brüggenjürgen B, Kohler S, Ezzat N, Reinhold T, Willich SN. Cost Effectiveness of Antiarrhythmic Medications in Patients Suffering from Atrial Fibrillation. PharmacoEconomics. 2013; 31(3):195-213.
Ellwanger E, Kim H, and Goss T (September 2014). The Value of Innovation in HIV/AIDs Therapy. White Paper: Pharmaceutical Research and Manufacturers of America (PhRMA).
Fusfeld L, Aggarwal J, Dougher C, Vera-Llonch M, Bubb S, Donepudi M, Goss TF (2013, May). Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. BMC Infectious Diseases, 13(1):234.
Sweeney N, Goss T. (2015, May) The Value of Innovation in Oncology: Recognizing Emerging Benefits Over Time.
Vachani A, Tanner NT, Aggarwal J, Mathews C, Kearney P, Fang KC, Silvestri G, Diette GB (2014, November 11). Factors That Influence Physician Decision-making for Indeterminate Pulmonary Nodules. Annals of the American Thoracic Society [online ahead of print]; DOI: 10.1513/AnnalsATS.201405-197BC.
Sample Case Studies
- Pre-Launch Market Analytics for a Specialty Pharmaceutical
- Reimbursement Assessment for Product Launch
- Reimbursement Strategy for Novel Breast Cancer Test
- IVD Business Development Strategy
- Implementation Strategy to Influence Technology Adoption and Increase Reimbursement in Multiple Sites of Care
- Assessment of US Reimbursement Environment for Specialty Pharmaceuticals
Addressing Increased Cost of Clinical Development with Innovative Approaches to Trial Design & Execution
Presented by Joseph Ferrara, President, Boston Healthcare and Vicki Anastasi, Senior VP Medical Devices, Aptiv Solutions
Companion Diagnostics: Aligning Development, Commercialization, and Market Access – Webinar
Presented by Thomas F. Goss, PharmD, Senior Vice President and Charles Mathews, Vice President of Boston Healthcare
Embedding Health Economics and Reimbursement into Medical Device Product Development and Portfolio Management
Presented by Rob Wenthold, Executive Director, Boston Healthcare